Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival

British Journal of Cancer

Volumn 98, Issue 7, 2008, Pages 1197-1203

  Wright, J D ^a,c   Doan, T ^b   McBride, R ^a,b   Jacobson, J S ^b   Hershman, D L ^a,b,c  

^a College of Physicians and Surgeons ^*  (United States)

^b Columbia University ^*  (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Chemotherapy; Duration of chemotherapy; Ovarian cancer; Treatment delay

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; ELDERLY CARE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; THERAPY DELAY; TREATMENT DURATION; WOMEN'S HEALTH;

AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; EARLY DIAGNOSIS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 41649115608     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604298     Document Type: Article

References (46)

1. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide vs intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335: 1950-1955
2. Aletti GD, Long HJ, Podratz KC, Cliby WA (2007) Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol 104: 212-216
3. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43
4. Bach PB, Cramer LD, Warren JL, Begg CB (1999) Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341: 1198-1205
5. Bell RS, Roth YF, Gebhardt MC, Bell DF, Rosenberg AE, Mankin HJ, Suit HD (1988) Timing of chemotherapy and surgery in a murine osteosarcoma model. Cancer Res 48: 5533-5538
6. Bristow RE, Zahurak ML, del Carmen MG, Gordon TA, Fox HE, Trimble EL, Montz FJ (2004) Ovarian cancer surgery in Maryland: volume-based access to care. Gynecol Oncol 93: 353-360
7. Bruchim I, Altaras M, Fishman A (2002) Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 86: 274-278
8. Carney ME, Lancaster JM, Ford C, Tsodikov A, Wiggins CL (2002) A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not? Gynecol Oncol 84: 36-42
9. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense vs conventionally scheduled and sequential vs concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21: 1431-1439
10. Cold S, During M, Ewertz M, Knoop A, Moller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer 93: 627-632
11. Colleoni M, Bonetti M, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner J, Collins J, Thurlimann B, Holmberg S, Veronesi A, Marini G, Goldhirsch A (2000) Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. J Clin Oncol 18: 584-590
12. Conte PF, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G, Ragni N, Rosso R, Rugiati S, Rubagotti A (1996) High-dose vs low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14: 351-356
13. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613-619
14. Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A, Trimble EL, Bodurka DC, Bristow RE, Carney M, Warren JL (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98: 172-180
15. Efstathiou E, Dimopoulos MA, Bozas G, Kastritis E, Moulopoulos LA, Rodolakis A, Vlahos G, Gika D, Papadimitriou C, Bamias A (2007) Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res 27: 611-617
16. Elit L, Bondy SJ, Paszat L, Przybysz R, Levine M (2002) Outcomes in surgery for ovarian cancer. Gynecol Oncol 87: 260-267
17. Fisher B, Gunduz N, Saffer EA (1983) Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 43: 1488-1492
18. Flynn PM, Paul J, Cruickshank DJ (2002) Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer? Gynecol Oncol 86: 354-357
19. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Maggioni A, Cosio S, Frassi E, LaPresa MT, Fuso L, Cristofani R (2005) Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study. J Clin Oncol 23: 751-758
20. Goff BA, Matthews BJ, Larson EH, Andrilla CH, Wynn M, Lishner DM, Baldwin LM (2007) Predictors of comprehensive surgical treatment in patients with ovarian cancer. Cancer 109: 2031-2042
21. Goff BA, Matthews BJ, Wynn M, Muntz HG, Lishner DM, Baldwin LM (2006) Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol 103: 383-390
22. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 16: 2426-2434
23. Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, Dale DC, Lyman GH (2007) Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25: 2522-2527
24. Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol 21: 3488-3494
25. Hershman D, Hall MJ, Wang X, Jacobson JS, McBride R, Grann VR, Neugut AI (2006a) Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 107: 2581-2588
26. Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, Neugut AI (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23: 6639- 6646
27. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006b) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99: 313-321
28. Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L (1999) 5-year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: a phase II study. J Clin Oncol 17: 1118
29. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, Nielsen K, Sandberg E, Stroeyer I (1997) Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol 15: 193-198
30. Junor EJ, Hole DJ, McNulty L, Mason M, Young J (1999) Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 106: 1130-1136
31. Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J Clin Epidemiol 53: 1258-1267
32. Klabunde CN, Warren JL, Legler JM (2002) Assessing comorbidity using claims data: an overview. Med Care 40, IV- 26-35
33. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel vs moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001-1007
34. McGuire WP, Hoskins WJ, Brady MF, Homesley HD, Creasman WT, Berman ML, Ball H, Berek JS, Woodward J (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13: 1589-1599
35. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
36. McGuire WP (1997) How many more nails to seal the coffin of dose intensity? Ann Oncol 8: 311-313
37. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R (1989) Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 7: 457-465
38. Paulsen T, Kaern J, Kjaerheim K, Haldorsen T, Trope C (2006a) Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer. Gynecol Oncol 102: 447- 452
39. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C (2006b) Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer 16(Suppl 1): 11-17
40. Schrag D, Earle C, Xu F, Panageas KS, Yabroff KR, Bristow RE, Trimble EL, Warren JL (2006) Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst 98: 163-171
41. Shannon C, Ashley S, Smith IE (2003) Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol 21: 3792-3797
42. Sundararajan V, Hershman D, Grann VR, Jacobson JS, Neugut AI (2002) Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20: 173-178
43. Tingulstad S, Skjeldestad FE, Hagen B (2003) The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol 102: 499-505
44. Vernooij F, Heintz P, Witteveen E, van der Graaf Y (2007) The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecol Oncol 105: 801-812
45. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, Cooper GS, Knopf KB (2002) Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 40, IV- 55-61
46. Warwick J, Kehoe S, Earl H, Luesley D, Redman C, Chan KK (1995) Longterm follow-up of patients with advanced ovarian cancer treated in randomised clinical trials. Br J Cancer 72: 1513-1517